# A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma

> **NCT04740034** · PHASE1 · TERMINATED · sponsor: **Amgen** · enrollment: 42 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** AMG 340

## Key facts

- **NCT ID:** NCT04740034
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-29
- **Primary completion:** 2024-06-24
- **Final completion:** 2024-06-24
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** Sponsor strategic decision
- **Last updated:** 2025-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04740034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04740034, "A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04740034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*